Journal
HUMAN VACCINES
Volume 7, Issue 3, Pages 349-356Publisher
LANDES BIOSCIENCE
DOI: 10.4161/hv.7.3.14266
Keywords
antibody; nicotiana; products; manufacturing; transient expression; glycan modification
Categories
Funding
- NIAID [AI62150, AI061270, AI063681, AG025641]
- NIA
Ask authors/readers for more resources
Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available